Growing CKD Prevalence Will Fuel Global Oral Therapy Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
23 Aug 25
Updated
23 Aug 25
AnalystHighTarget's Fair Value
US$10.00
69.7% undervalued intrinsic discount23 Aug
US$3.03
1Y
95.5%7D
-2.6%